• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Date set for arbitration trial between CEL-SCI and inVentiv

Date set for arbitration trial between CEL-SCI and inVentiv

January 7, 2015
CenterWatch Staff

CEL-SCI, a biotechnology company based in Vienna, Va., has announced that the trial in its ongoing arbitration against CRO inVentiv Clinical currently is scheduled for May 4.

CEL-SCI initiated an arbitration claim against inVentiv in October 2013. CEL-SCI initially retained inVentiv to conduct the phase III clinical trial of CEL-SCI's investigational drug Multikine (Leukocyte Interleukin Injection). CEL-SCI terminated inVentiv in or about April 2013 and replaced inVentiv with new CROs.

CEL-SCI's arbitration claim is initiated under the Commercial Rules of the American Arbitration Association alleging breach of contract, fraud in the inducement and common law fraud, and seeks at least $50 million in damages.

Multikine is an investigational immunotherapeutic agent being tested in a pivotal phase III clinical trial as a potential first-line treatment for advanced primary head and neck cancer. If approved, CEL-SCI said Multikine would be a different type of therapy in the fight against cancer—one that appears to have the potential to work with the body's natural immune system in the fight against tumors. CEL-SCI is aiming to complete enrollment of subjects to the phase III head and neck cancer study by the end of 2015. The trial is expected to expand to approximately 100 clinical centers in 20 countries.

In October 2013, CEL-SCI signed a CRADA (Cooperative Research and Development Agreement) with the US Naval Medical Center San Diego to develop Multikine as a potential treatment for HIV/HPV co-infected men and women with peri-anal warts. CEL-SCI also entered into two new co-development agreements with Ergomed to further clinically develop Multikine for cervical dysplasia/neoplasia in women co-infected with HIV and HPV and for peri-anal warts in men and women co-infected with HIV and HPV.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing